Pharmaceutical companies have paid billions of dollars to settle federal allegations of fraud and other wrongdoing in recent years.

In 2009, Eli Lilly and Company agreed to pay a 1.4 billion fine to resolve allegations of off-label promotion of Zyprexa, according to the U.S. Department of Justice (DOJ) website.

In 2012, GlaxoSmithKline agreed to plead guilty and pay a $3 billion fine to resolve fraud allegations and failure to report safety data, the DOJ said.

Continue Reading

Recently, a federal jury ordered Takeda Pharmaceutical Co. and Eli Lilly and Company to pay a total of $9 billion in punitive damages after finding that the companies had concealed cancer risks associated with pioglitazone, a diabetes drug.